Centrum Terapii Wspolczesnej

Lodz 90-338

1 studies enrolling now · 11 studies all time

What they study most

Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency), Atrial Fibrillation, Cardiovascular Risk, Chronic Kidney Disease, Early Breast Cancer, Inflammation, Metastatic Breast Cancer, Metastatic Non Small Cell Lung Cancer, Obesity, Overweight, Partial Epilepsy, Prevention of Stroke or Systemic Embolism

Studies at this site

• Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies — Recruiting now
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus — Completed
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis — Completed
• Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures — Completed
• A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) — Completed